Palvella Therapeutics (PVLA) Non-Current Debt (2013 - 2014)

Palvella Therapeutics' (PVLA) quarterly Non-Current Debt came in at $474.0 in Q3 2014, little changed on a QoQ basis from $474.0 in Q2 2014.

Palvella Therapeutics (PVLA) Non-Current Debt (2013 - 2014) Analysis & Trends

Palvella Therapeutics (PVLA) has 2 years of Non-Current Debt data on file, last reported at $474.0 in Q3 2014.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $474.0 in Q3 2014; TTM through Sep 2014 was $474.0, a N/A change from a year earlier, with the FY2014 full-year figure at $474.0, changed N/A from the prior year.
Non-Current Debt for Q3 2014 stood at $474.0, roughly flat from $474.0 in the prior quarter.
Over the last five years, Non-Current Debt for PVLA reached as high as $1.4 million in Q4 2013 and fell as low as $474.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Palvella Therapeutics	318.78 Mn	56.92 Mn	-	-

Download Data